Your browser doesn't support javascript.
loading
A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research.
Mendes, Bárbara B; Zhang, Zilu; Conniot, João; Sousa, Diana P; Ravasco, João M J M; Onweller, Lauren A; Lorenc, Andzelika; Rodrigues, Tiago; Reker, Daniel; Conde, João.
Afiliação
  • Mendes BB; ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas (NMS|FCM), Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Zhang Z; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Conniot J; ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas (NMS|FCM), Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Sousa DP; ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas (NMS|FCM), Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Ravasco JMJM; ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas (NMS|FCM), Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Onweller LA; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Lorenc A; Instituto de Investigação do Medicamento (iMed), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
  • Rodrigues T; Department of Biopharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
  • Reker D; Instituto de Investigação do Medicamento (iMed), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal. tiago.rodrigues@ff.ulisboa.pt.
  • Conde J; Department of Biomedical Engineering, Duke University, Durham, NC, USA. daniel.reker@duke.edu.
Nat Nanotechnol ; 19(6): 867-878, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38750164
ABSTRACT
Owing to their distinct physical and chemical properties, inorganic nanoparticles (NPs) have shown promising results in preclinical cancer therapy, but designing and engineering them for effective therapeutic purposes remains a challenge. Although a comprehensive database of inorganic NP research is not currently available, it is crucial for developing effective cancer therapies. In this context, machine learning (ML) has emerged as a transformative tool, but its adaptation to nanomedicine is hindered by inexistent or small datasets. Here we assembled a large database of inorganic NPs, comprising experimental datasets from 745 preclinical studies in cancer nanomedicine. Using descriptive statistics and explainable ML models we mined this database to gain knowledge of inorganic NP design patterns and inform future NP research for cancer treatment. Our analyses suggest that NP shape and therapy type are prominent features in determining in vivo efficacy, measured as a percentage of tumour reduction. Moreover, our database provides a large-scale open-access resource for discriminative ML that the broader nanotechnology community can utilize. Our work blueprints data mining for translational cancer research and offers evidence for standardizing NP reporting to accelerate and de-risk inorganic NP-based drug delivery, which may help to improve patient outcomes in clinical settings.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanomedicina / Nanopartículas / Aprendizado de Máquina / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanomedicina / Nanopartículas / Aprendizado de Máquina / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article